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Contrast-enhanced ultrasound in the diagnosis
of hepatocellular carcinomaq
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1Division of Diagnostic and Interventional Radiology, Department of Oncology, Transplants, and Advanced Technologies in Medicine,
University of Pisa, Pisa, Italy
2Division of Internal Medicine, Department of Internal Medicine and Gastroenterology, University of Bologna, Bologna, ItalySurveillance of patients at risk of developing hepatocellular carcinoma (HCC) is based on ultrasound (US) examinations
performed at either 6 or 12 month intervals. Early detection of HCC in patients with cirrhosis is a challenging issue, since
the diﬀerent entities that are involved in the multi-step process of hepatocarcinogenesis – such as low-grade and high-grade
dysplastic nodule – share common US features. Contrast-enhanced US allows reliable detection of arterial neoangiogen-
esis associated with a malignant transformation. Several reports have shown that the ability of contrast-enhanced US to
diagnose HCC currently approaches that of optimized multidetector computed tomography (CT) or dynamic magnetic res-
onance (MR) imaging protocols. The use of contrast-enhanced US to characterize nodular lesions in cirrhosis has been
recently recommended by the clinical practice guidelines issued by the European Federation of Societies for Ultrasound
in Medicine and Biology and the American Association for the Study of Liver Diseases. However, contrast-enhanced
US has not resulted in any signiﬁcant improvement in the ability of US to detect small tumor foci, since a comprehensive
assessment of the whole liver parenchyma cannot be accomplished during the short duration of the arterial phase. Hence,
CT or MR imaging are still mandatory for proper intrahepatic staging of the disease.
 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
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of hepatocellular carcinoma (HCC). According to the
European Association for the Study of the Liver (EASL)
and the American Association for the Study of Liver
Diseases (AASLD), US is the recommended tool for
surveillance of patients at risk of developing HCC
[1,2]. Moreover, US is the imaging technique most com-
monly used worldwide to guide biopsy on suspicious
nodules [3,4]. The introduction of US contrast agents
and the development of contrast-speciﬁc scanning tech-
niques have substantially increased the sensitivity and
speciﬁcity of US in the detection and characterization
focal liver lesions [5]. Recently, the European Federa-
tion of Societies for Ultrasound in Medicine and Biol-
ogy has issued recommendations for the use of
contrast agents in liver US, and the AASLD clinicalPublished by Elsevier B.V. All rights reserved.
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US – along with contrast-enhanced CT and contrast-
enhanced MR imaging – among the techniques that
can be used for non-invasive diagnosis of HCC in cir-
rhosis [2,6]. In this article, we review basic principles
and techniques of contrast-enhanced US of the liver
and we discuss advantages and limitations of contrast-
enhanced US with respect to the other imaging modali-
ties in the HCC setting.Table 1
Phases of contrast-enhancement in liver US imaging
Phase Starta (s) Enda (s)
Arterial phase 10–20 20–35
Portal venous phase 30–45 120–180
Late phase 120–180 240–360b
The individual global haemodynamic situation will inﬂuence the time
of onset of the three vascular phases.
a Time of visualization from start of contrast injection.
b Until microbubble disappearance.2. Basic principles
US contrast agents are stabilized microbubbles con-
taining either air (ﬁrst-generation contrast agents) or
other gases (second-generation contrast agents). Con-
trast-speciﬁc techniques are based on the complex
interactions between microbubbles and US beam. The
major determinant of this interaction is the peak nega-
tive pressure of the transmitted US pulse, grossly
reﬂected in the mechanical index. By scanning with a
low peak pressure, microbubbles behave as linear back-
scatterers, alternatively contracting and expanding
according to the positive and negative pressures of
the sinusoidal sound waves. This results in a simple
reﬂection of US echoes. As the incident peak pressure
increases, microbubbles show non-linear characteris-
tics, and start emission of harmonics. Harmonics are
created since on the negative portion of the sound
waves, microbubbles can become quite large, but on
the positive portion there is a limit at which they can
be compressed: this asymmetry is what constitutes the
harmonic emission. With further increase in the peak
pressure of the incident US ﬁeld, however, the shell
of the microbubbles is disrupted [5].
Contrast-speciﬁc techniques suppress linear US sig-
nals coming from tissues and use the non-linear response
of microbubbles to enhance signals from the contrast
agent over the background. The advent of second-gener-
ation agents has been instrumental in improving the ease
and the reproducibility of the examination, since low
solubility gases oﬀer improved stability and more
favourable resonance behaviour than air at low acoustic
pressure [7]. Hence, contrast-speciﬁc imaging can be per-
formed at a low mechanical index, thus preventing
microbubbles disruption and enabling visualization of
the dynamic enhancement pattern in real time over sev-
eral minutes.
Unlike iodinated contrast agents for CT and gadolin-
ium chelates for MR imaging, US contrast agents are
not cleared by the kidneys. Therefore, it is not necessary
to perform any laboratory test of renal function before
administering them. In general, US contrast agents are
very safe with a low incidence of side-eﬀects. Serious
adverse events in abdominal applications have been
reported with a rate of 0.0086% [8].3. Technique
A full assessment of the liver with baseline US is man-
datory before i.v. injection of the contrast. Then, con-
trast-speciﬁc imaging mode at low mechanical index is
selected. This will ensure adequate cancellation of tissue
signals, with only major vascular structures and some
anatomical landmarks such as the diaphragm remaining
barely visible. In some equipment, simultaneous display
of tissue and contrast signals has been implemented to
ensure that a lesion seen on contrast-enhanced imaging
can be concurrently detailed on conventional B-mode.
The US contrast agent is administered intravenously
via bolus injection followed by saline ﬂush. Because of
the dynamic nature of real time contrast-enhanced US,
the investigation should be documented on video or dig-
ital media, storing clips for each vascular phase [6]. Com-
plete examination of the liver using various sweeps is
possible within a time frame of approximately 4–5 min.
Enhancement patterns at contrast-enhanced US are
typically described during subsequent vascular phases
(arterial phase, portal venous phase, and late phase),
similar to contrast-enhanced CT or contrast-enhanced
MR imaging (Table 1). An inherent advantage of US
is the possibility to assess the contrast enhancement pat-
terns in real time, with a substantially higher temporal
resolution than CT or MR imaging and avoiding the
need to predeﬁne scan time points or to perform
bolus-tracking. US contrast agents, however, have dif-
ferent pharmacokinetics with respect to iodinated con-
trast agents for CT and gadolinium chelates for MR
imaging. US microbubbles are conﬁned to the intravas-
cular space, whereas the majority of currently approved
contrast agents for CT and MR imaging are rapidly
cleared from the blood pool into the extracellular space
[9]. Hence, despite many similarities, the enhancement
pattern of a given lesion at contrast-enhanced US may
not be identical to that observed at CT or MR imaging
(Fig. 1).4. Detection of HCC
Surveillance programs aimed at early detection of
HCC in patients at risk are based on US examinations
Fig. 1. Enhancement patterns of HCC at contrast-enhanced US and
contrast-enhanced CT. The lesion shows clear-cut enhancement in the
arterial phase both in the contrast-enhanced CT (a) and the contrast-
enhanced US study (b). However, contrast wash-out in the portal venous
phase is better detected on CT (c) than on US (d). In the late phase, the
tumor is hypoenhanced both on CT (e) and on US (f).
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Early detection of HCC, especially in patients with cir-
rhosis, is a challenging issue. Cirrhosis is characterized
by ﬁbrous septa and regenerative nodules. These fea-
tures produce a coarse pattern on US, that may impairidentiﬁcation of small tumors. Moreover, a comprehen-
sive assessment of the liver parenchyma may sometimes
be hampered by the patient’s body habitus, colonic
interposition, or morphologic changes induced by cir-
rhosis – such as retraction of the right liver lobe – which
reduce the ability to explore the liver via intercostal
scans. The ability to detect the emergence of a small
HCC is highly dependent on the expertise of the opera-
tor performing the examination and the availability of
state-of-the-art equipment. When these requirements
are met, surveillance has proved eﬀective in detecting
HCC at an early stage [12–15]. The value of US surveil-
lance performed in a primary care setting by operators
who do not have speciﬁc skills is questionable. If the
expertise is not available, the eﬃcacy of surveillance
will be lost. Upon detection of a suspicious nodule,
the recommended policy is to evaluate the patient in
referral centers with optimal human and technical
resources [1].
Unfortunately, the use of contrast-enhanced US did
not result in increased sensitivity US in the detection
of small HCC tumors. As a general rule, contrast-
enhanced US techniques are subject to the same limita-
tions as any other US mode: if the baseline scan is unsat-
isfactory, the contrast-enhanced US study will be
unsatisfactory as well [6]. In addition, as described later,
the greatest contrast between tumor and liver paren-
chyma is seen during the short time of the arterial phase.
While multidetector CT and dynamic MR sequences can
automatically image the entire liver parenchyma in a few
seconds, a comprehensive manual scanning of the whole
liver with US during the arterial phase is hardly attain-
able, even when performing repeated contrast injections.
Thus, there is currently no indication to use microbub-
ble contrast agents to increase the detection rate of
HCC in patients undergoing US surveillance [6].5. Characterization of HCC
Carcinogenesis is often a multi-step process in cirrho-
sis. This process includes progression from cirrhotic
nodule, to macroregenerative nodule, to low-grade dys-
plastic nodule (DN), to high-grade DN, to frank HCC
[16]. Progression along the multi-step pathway is charac-
terized by cytological and architectural changes [17].
Unfortunately, these entities show variable and overlap-
ping features at baseline US, making reliable diﬀerential
diagnosis impossible. Small HCC may appear hyperech-
oic, hypoechoic, or isoechoic with respect to the sur-
rounding parenchyma, and is usually undistinguishable
from macroregenerative nodule or DN. In addition,
small hyperechoic HCC may be undistinguishable from
hemangioma [18].
One of the key pathologic factors for diﬀerential diag-
nosis between HCC and non-malignant hepatocellular
Fig. 2. Doppler US study of HCC. Baseline US scan (a) shows the tumor as hypoechoic nodule with inﬁltrative pattern (calipers). At Doppler US (b),
ﬂow in the segmental portal vein branch is reverted and shows a pulsatile pattern at spectral analysis, indicating the presence of arterio-portal ﬁstula. Note
that the peak of portal ﬂow (shown below the zero line in the spectral tracing) is slightly delayed in comparison to that of the aﬀerent hepatic arterial
branch (above the zero line in the spectral tracing).
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cular supply to the nodule. The progression from mac-
roregenerative nodule, to low-grade DN, to high-grade
DN, to frank HCC, is characterized by loss of visualiza-
tion of portal tracts and development of new arterial ves-
sels, termed non-triadal arteries, which becomes the
dominant blood supply in overt HCC lesions [19–21].
This arterial neoangiogenesis is the landmark of HCC
and is the key for imaging diagnosis [22,23].
Doppler US techniques have long been used in
attempts to evaluate tumor vascularity in HCC [24–
27]. At color or power Doppler US, large HCC is
usually displayed as a vascular-rich lesion containing
intratumoral ﬂow signals with an arterial Doppler
spectrum. A basket pattern, which is a ﬁne blood-ﬂow
network surrounding the nodule, and tumor vessels
ﬂowing into the lesion and branching within it are
typically observed. Doppler interrogation shows a pul-
satile Doppler waveform with high frequency shifts
(>1 kHz) and abnormally elevated resistive index
(>0.71) [25,27]. Creation of arterio-portal ﬁstula canTable 2
Studies comparing contrast-enhanced US with multidetector CT or dynamic M
lesions in cirrhosis
Author No. lesions Lesion size
Gaiani et al. [34] 103 2.8 ± 1.3
Bolondi et al. [35] 41 1–2
31 2–3
Forner et al. [36] 60 0.5–2
a This series included only tumors showing arterial hypervascularity in mube occasionally demonstrated (Fig. 2). In contrast,
macroregenerative nodule and DN either do not have
any detectable intratumoral vascularity or show arte-
rial vessels with low frequency shifts and normal resis-
tive index [28]. However, in small HCC tumors, the
sensitivity of Doppler US in showing arterial neovas-
cularity is low, and abnormal ﬂow can be demon-
strated in less than 50% of the lesions [24,28]. In
addition, the technique is quite cumbersome and the
positive predictive value is not high [29].
Several reports have shown that contrast-enhanced
US is a tool to show arterial neoangiogenesis in HCC
[30–33]. HCC typically shows strong intratumoral
enhancement in the arterial phase, while macroregener-
ative nodule and DN usually do not show any early con-
trast uptake, and resemble the enhancement pattern of
liver parenchyma. The ability of contrast-enhanced US
to show arterial hypervascularization appears to
approach that of optimized multidetector CT or
dynamic MR imaging protocols, provided that the nod-
ule can be clearly identiﬁed on baseline scans (Table 2).R imaging in the ability to detect arterial hypervascularization in nodular
(cm) Detection rate
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rial hypervascularity at CT were included, the sensitivity
of contrast-enhanced US in the detection of arterial
hyperenhancement was 91% [34]. In two comparative
analyses including consecutive patients with small nod-
ules in cirrhosis detected during surveillance, contrast-
enhanced US was superior to multidetector CT and
slightly inferior to dynamic MR imaging in showing
the presence of arterial hypervascularity (Table 2)
[35,36].
Unfortunately, the sole detection of arterial hyper-
vascularity in a small nodular lesion emerged in a cir-
rhotic liver – although suspicious for HCC – may notFig. 3. Non-invasive diagnosis of very-early HCC in cirrhosis. Baseline US sho
US shows clear-cut enhancement in the arterial phase (b) with rapid wash-o
multidetector CT scans obtained in the arterial phase (d) and the portal venoube considered as a conclusive ﬁnding. It is well
established that non-malignant hepatocellular lesions –
especially high-grade DN – may show arterial hypervas-
cularization on imaging [37,38]. Small, high-ﬂow
hemangioma may also appear as a hyperenhancing
nodule [39]. A recent investigation has shown that in
the setting of cirrhotic patients undergoing surveillance,
the sole imaging ﬁnding of arterial hypervascularization
in small solitary nodules of 2 cm or less has a speciﬁcity
of 86% and a positive predictive value of 92% for the
diagnosis of HCC [36]. To increase the speciﬁcity of
imaging diagnosis, it is mandatory to evaluate contrast
wash-out during the portal venous and the late phase,ws 1.5-cm isoechoic nodule with hypoechoic halo (a). Contrast-enhanced
ut in the portal venous phase (c). The same ﬁndings are observed on
s phase (e).
Table 3
Studies comparing contrast-enhanced US with multidetector CT or dynamic MR imaging in the diagnosis of HCC in nodules 2 cm or smaller detected
during US surveillance
Author No. patients No. lesions Lesion size (cm) Sensitivity (%) Speciﬁcity (%)
Forner et al. [36] 60 60a 0.5–2
Contrast US 52 93
Dynamic MRI 62 97
Dai et al. [40] 72 103 1–2
Contrast US 91 87
Multidetector CT 80 98
Note. Figures refer to detection of typical enhancement pattern of HCC, i.e., arterial hypervascularization with venous wash-out.
a This series included only patients with solitary small tumors.
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on HCC and the AASLD practice guideline [2]. Con-
trary to non-malignant entities, HCC is characterized
by rapid wash-out of the contrast agent, and usually
appears hypoenhanced in the portal venous or the late
phase [36–38] (Fig. 3).
If strict criteria – including hypervascularization in
the arterial phase with wash-out in the portal venous
or the late phase – are used to diagnose HCC, the
very high speciﬁcity that can be obtained has the
downside of a reduced sensitivity in the diagnosis of
malignancy. In fact, the timing of contrast wash-out
in HCC appears to be correlated with the degree of
tumor diﬀerentiation. While moderately or poorly dif-
ferentiated tumors have fast contrast wash-out and
appear as defects in the portal venous or the late
phase, well-diﬀerentiated tumors may wash out slowly
and be isoenhanced with respect to the liver paren-
chyma in the portal venous or the late phase [41–
43]. Thus, diagnosis of small, well-diﬀerentiated
tumors remains a challenge. Nevertheless, this is the
case of any dynamic imaging technique, and the diag-
nostic accuracy of contrast-enhanced US for the diag-
nosis of HCC appears to be similar to that of
multidetector CT or dynamic MR imaging (Table 3)
[36,40].6. Intrahepatic staging
Accurate intrahepatic staging is essential for the
proper clinical management of patients with HCC, par-
ticularly given the propensity of HCC, even at early
stages, to produce satellite lesions via the invasion of
peripheral portal vein branches.
It is well established that US has limited sensitivity in
the detection of tiny satellite lesions. When careful imag-
ing-pathologic correlation on explanted livers was per-
formed, the sensitivity of US was as low as 14% in the
detection of lesions smaller than 2 cm, and as low as
0% for cancerous foci smaller than 1 cm [44,45].
Although these data have been mostly collected inpatients with advanced cirrhosis who underwent liver
transplantation – and therefore may not be applicable
to the general population of cirrhotic patients with
HCC – the rate of underestimation of the extent of the
disease with US is clearly unacceptable. Unfortunately,
as discussed earlier, the use of contrast agents did not
result in any signiﬁcant improvement in the ability of
US to detect small tumors [6]. The duration of the arte-
rial phase – during which HCC tumors stand out against
the faintly enhanced liver parenchyma – is far too short
to allow a comprehensive manual scanning of the entire
organ. In the portal venous and the late phase – con-
trary to hepatic metastases – the contrast between tumor
and liver is usually low, preventing identiﬁcation of
small tumors not detected on baseline scans. Thus, even
in the era of contrast-enhanced US, the use of either
multidetector CT or dynamic MR imaging for intrahe-
patic staging of HCC is a mandatory step before thera-
peutic planning [23,46].
In large HCC tumors, thrombosis of portal vein
branches due to tumor invasion is commonly observed
on imaging. However, in the setting of liver cirrhosis,
portal vein thrombosis has a prevalence of about 5%,
even in the absence of HCC [47]. In patients with
HCC, distinction between malignant and non-malignant
portal vein thrombosis is of paramount importance, as
vascular invasion determines the shift from intermedi-
ate-stage to advanced-stage according to the Barcelona
Clinic Liver Cancer (BCLC) staging system [48]. Recent
observations have shown that contrast-enhanced US
may be a tool for this purpose [49,50]. Unlike bland
thrombosis, malignant thrombi show the typical fea-
tures of HCC, and show rapid enhancement in the arte-
rial phase due to the presence of hypervascularized
tumor tissue (Fig. 4). In one study including 54 consec-
utive patients who had cirrhosis, biopsy-proven HCC,
and thrombosis of the portal trunk or the main right
or left branches, contrast-enhanced US showed absolute
speciﬁcity and higher sensitivity than ﬁne-needle biopsy
in showing the malignant nature of the thrombus [49]. In
another series of 34 patients listed for transplantation
for HCC on cirrhosis, who also showed thrombosis of
Fig. 4. Malignant portal vein thrombosis. Baseline US (a) shows tiny echoic thrombus (calipers) inside the left portal vein in patients with HCC. Signal
from tissues is suppressed in the contrast-speciﬁc US image (b). Clear-cut contrast uptake of the thrombus is observed in the arterial phase of the contrast-
enhanced study, suggesting the malignant nature of the thrombus (c). In the portal phase, the portal lumen ﬁlls with contrast, and the thrombus is no longer
recognizable (d).
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enhanced US was able to accurately exclude the malig-
nant nature of the thrombus, as conﬁrmed by pathologic
analysis of the explanted organs [50].7. Diagnostic work-up
The detection of a nodular lesion during US sur-
veillance should always raise the suspicion of HCC
[1,2]. However, pathologic studies have shown that a
signiﬁcant proportion of small nodules detected byUS in cirrhotic livers do not correspond to HCC,
but rather to non-malignant hepatocellular nodules.
Percutaneous US-guided biopsy could appear as the
most straightforward approach to diﬀerentiate HCC
from non-malignant hepatocellular lesions. Unfortu-
nately, the biopsy of small nodular lesions in cirrhosis
is not entirely reliable. In fact, needle placement may
be diﬃcult and a sampling error may occur. More-
over, it is very diﬃcult to distinguish well-diﬀerenti-
ated HCC from DN on small biopsy specimens, as
there is not a clear-cut dividing line between dysplasia
and well-diﬀerentiated tumor [51]. Therefore, a
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– is helpful, but a negative biopsy can never be taken
as a criterion to rule out malignancy [1,2]. In addition,
biopsy is associated with a low but not negligible rate
of complications, including tumor seeding along the
needle track.
Both the 2005 EASL conference on HCC and the
AASLD practice guideline have recommended to fur-
ther investigate nodules detected during US surveillance
with dynamic imaging techniques – including contrast-
enhanced US, multidetector CT, or dynamic MR imag-
ing – to highlight the diﬀerent vascular supply of HCC
versus non-malignant entities [2]. However, the diagnos-
tic protocol should be structured according to the actual
risk of malignancy and the possibility to achieve a reli-
able diagnosis. Since the prevalence of HCC among
US-detected nodules is strongly related to the size of
the lesion, the diagnostic work-up depends on the size
of the lesion [2]. Lesions smaller than 1 cm in diameter
have a low likelihood of being HCC. However, such
minute nodules may become malignant over time.
Therefore, these lesions need to be followed up in order
to detect growth suggestive of malignant transforma-
tion. A reasonable protocol is to repeat US every 3
months, until the lesion grows to more than 1 cm, at
which point additional diagnostic techniques are applied
[1,2]. It has to be emphasized, however, that the absence
of growth during the follow-up period does not rule out
the malignant nature of the nodule because an early
HCC may occasionally take more than one year to
increase in size [1].
When the nodule exceeds 1 cm in size, the lesion is
more likely to be HCC and diagnostic conﬁrmation
should be pursued. It is accepted that the diagnosis of
HCC can be made without biopsy in a lesion larger than
1 cm that shows characteristic vascular features of HCC
– i.e., arterial hypervascularization with washout in the
portal venous or the late phase – even in patients with
normal alpha-fetoprotein values [2]. While for lesions
above 2 cm a single imaging technique showing the char-
acteristic vascular proﬁle of HCC mentioned above may
conﬁdently establish the diagnosis, in lesions ranging 1–
2 cm, AASLD guidelines recommend that typical imag-
ing ﬁndings are conﬁrmed by two coincident dynamic
imaging modalities to allow a non-invasive diagnosis
[2]. Such lesions ranging 1–2 cm are the true target of
screening programs, as they identify the population of
patients with very-early HCC tumors, who have the
highest likelihood for cure with surgical resection or per-
cutaneous ablation [52]. Speciﬁcity of imaging diagnosis
is crucial to prevent therapeutic errors due to false-posi-
tive diagnoses of malignancy.
The combination of contrast-enhanced US and mul-
tidetector CT (or contrast-enhanced US and dynamic
MR imaging) appears as the most rationale for non-
invasive diagnosis of small tumors. This is clearly themost cost-eﬀective combination, as the contrast-
enhanced US study can be performed immediately upon
the detection of a focal lesion at baseline US, and only
one additional examination (either CT or MR imaging)
is needed as a conﬁrmatory test. In addition, given the
diﬀerent pharmacokinetics of US contrast agents
(blood-pool compounds) with respect to CT and MR
imaging contrast agents (extracellular ﬂuid space com-
pounds), such a combination provides complementary
information. In a prospective validation of AASLD cri-
teria conducted in a series of consecutive patients with a
solitary focal lesion smaller than 2 cm detected during
US surveillance, the combined use of contrast-enhanced
US and dynamic MR imaging achieved 100% speciﬁcity
for the diagnosis of HCC [36].
If the lesion does not show typical features of HCC,
or the vascular proﬁle is not coincidental between the
imaging techniques, biopsy is recommended [2]. It is
important to point out that the absence of arterial
hypervascularization on imaging does not rule out
HCC. It is well established that HCC tumors at a
very-early stage may not exhibit the characteristic vascu-
lar features of overt HCC [35]. Delaying the diagnosis of
HCC until imaging detection of arterial hypervascular-
ization could reduce the chances of radical cure, since
the incidence of microscopic vascular invasion and satel-
lite nodules signiﬁcantly increases when tumor exceeds
2 cm and develops imaging-detectable neoangiogenesis
[17]. As a matter of fact, in the setting of cirrhotic
patients in whom a solitary nodule smaller than 2 cm
is detected during US surveillance, biopsy is still needed
in about two-thirds of the cases, and – given the well-
known limitations of pathology reading – repeated biop-
sies are needed in as many as 30% of cases [36]. This is
the area where advances in imaging techniques based
on liver-speciﬁc contrast agents (including hepatocyte-
targeted agents and reticuloendothelial system-targeted
agents) should be further investigated [53] and research
on new diagnostic tools – based on immunostaining,
gene expression assessment, or protein proﬁling – will
have to focus [54].References
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